The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
Open accessAbstract
Allelic losses on the chromosome arms 1p and 19q have been associated with favorable response to chemotherapy and good prognosis in anaplastic oligodendroglioma patients, but the molecular mechanisms responsible for this relationship are as yet unknown. The DNA repair enzyme O 6‐methylguanine DNA methyltransferase (MGMT) may cause resistance to DNA‐alkylating drugs commonly used in the treatment of anaplastic oligodendrogliomas and other malignant gliomas. We report on the analysis of 52 oligodendroglial tumors for MGMT promoter methylation, as well as mRNA and protein expression. Using sequencing of sodium bisulfite‐modified DNA, we determined the methylation status of 25 CpG sites within the MGMT promoter. In 46 of 52 tumors (88%), we detected MGMT promoter hypermethylation as defined by methylation of more than 50% of the sequenced CpG sites. Real‐time reverse transcription‐PCR showed reduced MGMT mRNA levels relative to non‐neoplastic brain tissue in the majority of tumors with hypermethylation. Similarly, immunohistochemical analysis showed either no or only small fractions of MGMT positive tumor cells. MGMT promoter hypermethylation was significantly more frequent and the percentage of methylated CpG sites in the investigated MGMT promoter fragment was significantly higher in tumors with loss of heterozygosity on chromosome arms 1p and 19q as compared to tumors without allelic losses on these chromosomes arms. Taken together, our data suggest that MGMT hypermethylation and low or absent expression are frequent in oligodendroglial tumors and likely contribute to the chemosensitivity of these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Temozolomide and treatment of malignant glioma
Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · doi:10.25405/ncl.34644405 · Cited by 731
REIFENBERGER, J., Reifenberger, G., Liu, L., James, C. D., Wechsler, W., & Collins, V. P. (1994) · PubMed Central · Cited by 601
Self-citationEsteller, M., & Herman, J. G. (2004) · Oncogene · doi:10.1038/sj.onc.1207316 · Cited by 326
van den Boom, J., Wolter, M., Kuick, R., Misek, D. E., Youkilis, A. S., Wechsler, D. S., Sommer, C., Reifenberger, G., & Hanash, S. M. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63463-3 · Cited by 307
Self-citationOligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro-Oncology
Reifenberger, G., & Louis, D. N. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.2.111 · Cited by 296
Self-citationWatts, G. S., Pieper, R. O., Costello, J. F., Peng, Y.-M., Dalton, W. S., & Futscher, B. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5612 · Cited by 214
Costello, J. F., Futscher, B. W., Tano, K., Graunke, D. M., & Pieper, R. O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32544-9 · Cited by 200
Felsberg, J., Erkwoh, A., Sabel, M. C., Kirsch, L., Fimmers, R., Blaschke, B., Schlegel, U., Schramm, J., Wiestler, O. D., & Reifenberger, G. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00044.x · Cited by 173
Self-citationGenetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications
Smith, J. (2000) · Frontiers in Bioscience · doi:10.2741/smith · Cited by 160
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide
Kanzawa, T., Bedwell, J. R., Kondo, Y., Kondo, S., & Germano, I. M. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.99.6.1047 · Cited by 155
Balañá, C., Ramírez, J. L., Tarón, M., Roussos, Y., Ariza, A., Ballester, R., Sarries, C., Méndez, P., Sánchez, J. J., & Rosell, R. (2003) · PubMed · Cited by 145
Silber, J. R., Bobola, M. S., Ghatan, S., Blank, A., Kolstoe, D. D., & Berger, M. S. (1998) · PubMed · Cited by 144
Komine, C., Watanabe, T., Katayama, Y., Yoshino, A., Yokoyama, T., & Fukushima, T. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00017.x · Cited by 135
Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas
Watanabe, T., Nakamura, M., Kros, J. M., Burkhard, C., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2001) · Acta Neuropathologica · doi:10.1007/s004010100464 · Cited by 134
Concurrent Hypermethylation of Multiple Genes Is Associated with Grade of Oligodendroglial Tumors
Dong, S.-M., Pang, J. C., Poon, W. S., Hu, J., To, K., Chang, A. R., & Ng, H. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.808 · Cited by 120
DNA repair in resistance to alkylating anticancer drugs
Kaina, B., & Christmann, M. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40354 · Cited by 117
Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas
Alonso, M. E., Bello, M. J., González‐Gómez, P., Arjona, D., Lomas, J., de Campos, J. M., Isla, A., Sarasa, J. L., & REY, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00928-7 · Cited by 114
Wolter, M., REIFENBERGER, J., Blaschke, B., Ichimura, K., Schmidt, E., Collins, V. P., & Reifenberger, G. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.12.1170 · Cited by 98
Self-citationNutt, C. L., Noble, M., Chambers, A. F., & Cairncross, J. G. (2000) · PubMed · Cited by 89
Promoter hypermethylation of multiple genes in astrocytic gliomas
González‐Gómez, P., Bello, M. J., Arjona, D., et al. (2003) · International Journal of Oncology · doi:10.3892/ijo.22.3.601 · Cited by 85
Recent developments in the molecular characterization and treatment of oligodendroglial tumors
van den Bent, M. J., Chinot, O. L., & Cairncross, J. G. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.128 · Cited by 79
Cellular mechanisms targeted during astrocytoma progression
Collins, V. P. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00198-2 · Cited by 27
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Long-term survival with glioblastoma multiforme
Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., et al. (2007) · Brain · doi:10.1093/brain/awm204 · Cited by 887
Self-citationHegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Self-citationMGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
Self-citation
Metadata
- Authors
- Möllemann, M., Wolter, M., Felsberg, J., Collins, V. P., & Reifenberger, G.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-09-28
- Volume
- 113
- Issue
- 3
- Pages
- 379-385
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2074242592
- Cited by
- 278
- References
- 30
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.